Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Proteomics
  4. Volume 21, Issue 4
  5. Article
Volume 21, Issue 4
  • ISSN: 1570-1646
  • E-ISSN: 1875-6247

Abstract

Adropin is 76-amino acids protein. It was discovered in 2008. Adropin expression was found in the liver, brain, heart, kidneys, pancreas, testis and ovary, umbilical vein, coronary artery endothelial cells, aortic smooth muscle cells and monocytes/macrophages. Adropin is involved in energy balance, and it has an endothelial protective effect. Changes in adropin content have been found in many diseases and disorders, such as obesity, diabetes mellitus type 1 and 2, coronary artery disease, myocardial infarction, rheumatoid arthritis, primary Sjögren's syndrome, multiple sclerosis, nonalcoholic fatty liver disease, polycystic ovary syndrome and preeclampsia. This mini-review focuses on those papers that have potential implications for clinical diagnosis or possible treatment. It can be assumed that adropin can be useful in the diagnosis of certain diseases. It seems to be a promising candidate for the treatment of diabetes, atherosclerosis, polycystic ovary syndrome and diseases of the nervous system associated with cognitive decline.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cp/10.2174/0115701646301720240830070246
2024-12-01
2024-11-18

  • From This Site

    /content/journals/cp/10.2174/0115701646301720240830070246
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AydinS. Three new players in energy regulation: Preptin, adropin and irisin.Peptides2014569411010.1016/j.peptides.2014.03.02124721335
     [Google Scholar]
  2. KumarK.G. TrevaskisJ.L. LamD.D. SuttonG.M. KozaR.A. ChouljenkoV.N. KousoulasK.G. RogersP.M. KestersonR.A. ThearleM. FerranteA.W.Jr MynattR.L. BurrisT.P. DongJ.Z. HalemH.A. CullerM.D. HeislerL.K. StephensJ.M. ButlerA.A. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.Cell Metab.20088646848110.1016/j.cmet.2008.10.01119041763
     [Google Scholar]
  3. BozicJ. KumricM. Ticinovic KurirT. MalesI. BorovacJ.A. MartinovicD. VilovicM. Role of adropin in cardiometabolic disorders: from pathophysiological mechanisms to therapeutic target.Biomedicines2021910140710.3390/biomedicines910140734680524
     [Google Scholar]
  4. AliI.I. D’SouzaC. SinghJ. AdeghateE. Adropin’s role in energy homeostasis and metabolic disorders.Int. J. Mol. Sci.20222315831810.3390/ijms2315831835955453
     [Google Scholar]
  5. Ganesh-KumarK. ZhangJ. GaoS. RossiJ. McGuinnessO.P. HalemH.H. CullerM.D. MynattR.L. ButlerA.A. Adropin deficiency is associated with increased adiposity and insulin resistance.Obesity (Silver Spring)20122071394140210.1038/oby.2012.3122318315
     [Google Scholar]
  6. ButlerA.A. St-OngeM.P. SiebertE.A. MediciV. StanhopeK.L. HavelP.J. Differential responses of plasma adropin concentrations to dietary glucose or fructose consumption in humans.Sci. Rep.2015511469110.1038/srep1469126435060
     [Google Scholar]
  7. JumperJ. EvansR. PritzelA. GreenT. FigurnovM. RonnebergerO. TunyasuvunakoolK. BatesR. ŽídekA. PotapenkoA. BridglandA. MeyerC. KohlS.A.A. BallardA.J. CowieA. Romera-ParedesB. NikolovS. JainR. AdlerJ. BackT. PetersenS. ReimanD. ClancyE. ZielinskiM. SteineggerM. PacholskaM. BerghammerT. BodensteinS. SilverD. VinyalsO. SeniorA.W. KavukcuogluK. KohliP. HassabisD. Highly accurate protein structure prediction with AlphaFold.Nature2021596787358358910.1038/s41586‑021‑03819‑234265844
     [Google Scholar]
  8. VaradiM. AnyangoS. DeshpandeM. NairS. NatassiaC. YordanovaG. YuanD. StroeO. WoodG. LaydonA. ŽídekA. GreenT. TunyasuvunakoolK. PetersenS. JumperJ. ClancyE. GreenR. VoraA. LutfiM. FigurnovM. CowieA. HobbsN. KohliP. KleywegtG. BirneyE. HassabisD. VelankarS. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models.Nucleic Acids Res.202250D1D439D44410.1093/nar/gkab106134791371
     [Google Scholar]
  9. MengE.C. GoddardT.D. PettersenE.F. UCSF ChimeraX: Tools for structure building and analysis.Protein Sci.2023, Sep 29:20232023e4792
     [Google Scholar]
  10. WongC.M. WangY. LeeJ.T.H. HuangZ. WuD. XuA. LamK.S.L. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice.J. Biol. Chem.201428937259762598610.1074/jbc.M114.57605825074942
     [Google Scholar]
  11. AydinS. KulogluT. AydinS. ErenM.N. YilmazM. KalayciM. Sahinİ. KocamanN. CitilC. KendirY. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes.Mol. Cell. Biochem.20133801-2738110.1007/s11010‑013‑1660‑423620340
     [Google Scholar]
  12. KulogluT. AydinS. Immunohistochemical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes.Biotech. Histochem.201489210411010.3109/10520295.2013.82171323957703
     [Google Scholar]
  13. TripathiS. MauryaS. SinghA. Adropin, a novel hepatokine: localization and expression during postnatal development and its impact on testicular functions of pre-pubertal mice.Cell Tissue Res.202310.1007/s00441‑023‑03852‑938087073
     [Google Scholar]
  14. MauryaS. TripathiS. SinghA. Ontogeny of adropin and its receptor expression during postnatal development and its pro-gonadal role in the ovary of pre-pubertal mouse.J. Steroid Biochem. Mol. Biol.202323410640410.1016/j.jsbmb.2023.10640437743028
     [Google Scholar]
  15. LovrenF. PanY. QuanA. SinghK.K. ShuklaP.C. GuptaM. Al-OmranM. TeohH. VermaS. Adropin is a novel regulator of endothelial function.Circulation201012211_suppl_1Suppl.S185S19210.1161/CIRCULATIONAHA.109.93178220837912
     [Google Scholar]
  16. SatoK. YamashitaT. ShiraiR. ShibataK. OkanoT. YamaguchiM. MoriY. HiranoT. WatanabeT. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation.Int. J. Mol. Sci.2018195129310.3390/ijms1905129329701665
     [Google Scholar]
  17. AydinS. KulogluT. AydinS. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus.Peptides201347667010.1016/j.peptides.2013.07.00123850897
     [Google Scholar]
  18. KurtE. TekinE. KurtN. BayramogluA. The role of adropin, HIF-1α and apelin biomarkers in the diagnosis of acute mesentaric ischemia.Am. J. Emerg. Med.20225122322710.1016/j.ajem.2021.10.05834775196
     [Google Scholar]
  19. YolbasS. KaraM. KalayciM. YildirimA. GundogduB. AydinS. KocaS.S. ENHO gene expression and serum adropin level in rheumatoid arthritis and systemic lupus erythematosus.Adv. Clin. Exp. Med.201827121637164110.17219/acem/7594430141839
     [Google Scholar]
  20. LianW. GuX. QinY. ZhengX. Elevated plasma levels of adropin in heart failure patients.Intern. Med.201150151523152710.2169/internalmedicine.50.516321804276
     [Google Scholar]
  21. KongZ. LiuY. Soluble vascular adhesion protein-1 level correlates with adropin and inflammatory biomarkers in patients with obstructive sleep apnea.Ear Nose Throat J.2022145561322107414710.1177/0145561322107414735261273
     [Google Scholar]
  22. ErmanH. OzdemirA. SitarM.E. CetinS.I. BoyukB. Role of serum adropin measurement in the assessment of insulin resistance in obesity.J. Investig. Med.20216971318132310.1136/jim‑2021‑00179634016737
     [Google Scholar]
  23. HosseiniA. ShanakiM. EmamgholipourS. NakhjavaniM. RaziF. GolmohammadiT. Elevated serum levels of adropin in patients with type 2 diabetes mellitus and its association with insulin resistance.J. Biol. Todays World201653444910.15412/J.JBTW.01050301
     [Google Scholar]
  24. Es-haghiA. Al-AbyadhT. Mehrad-MajdH. The clinical value of serum adropin level in early detection of diabetic nephropathy.Kidney Blood Press. Res.202146673474010.1159/00051917334644709
     [Google Scholar]
  25. ChenX. SunX. ShenT. ChenQ. ChenS. PangJ. MiJ. TangY. YouY. XuH. LingW. Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease.Free Radic. Biol. Med.202016019119810.1016/j.freeradbiomed.2020.08.00532810635
     [Google Scholar]
  26. DanolićM.J. PerkovićD. PetrićM. BarišićI. GugoK. BožićJ. Adropin serum levels in patients with primary Sjögren’s syndrome.Biomolecules2021119129610.3390/biom1109129634572509
     [Google Scholar]
  27. ZangH. JiangF. ChengX. XuH. HuX. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index.Endocr. J.201865768569110.1507/endocrj.EJ18‑006029669965
     [Google Scholar]
  28. LiS. SunJ. HuW. LiuY. LinD. DuanH. LiuF. The association of serum and vitreous adropin concentrations with diabetic retinopathy.Ann. Clin. Biochem.201956225325810.1177/000456321882035930514096
     [Google Scholar]
  29. SimacP. PerkovicD. BozicI. BilopavlovicN. MartinovicD. BozicJ. Serum adropin levels in patients with rheumatoid arthritis.Life (Basel)202212216910.3390/life1202016935207457
     [Google Scholar]
  30. PolkowskaA. PasierowskaI.E. PasławskaM. PawluczukE. BossowskiA. Assessment of serum concentrations of adropin, afamin, and neudesin in children with type 1 diabetes.BioMed Res. Int.201920191610.1155/2019/612841031781629
     [Google Scholar]
  31. HuW. ChenL. Association of serum adropin concentrations with diabetic nephropathy.Mediators Inflamm.201620161510.1155/2016/603826127546995
     [Google Scholar]
  32. LiB. TianX. GuoS. ZhangM. LiJ. ZhaiN. WangH. ZhangY. Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients.Int. Urol. Nephrol.202052112145215210.1007/s11255‑020‑02568‑x32661627
     [Google Scholar]
  33. KaracaE. ErcanC.C. AkdemirC. SivrikozT.S. SalmasliogluA. VeritF.F. GurdolF. OmerB. The evaluation of adropin and autotaxin as potential markers of endothelial dysfunction in preeclampsia.Angiology202333197231183228Online ahead of print10.1177/0003319723118322837587899
     [Google Scholar]
  34. BeigiA. ShirzadN. NikpourF. Nasli EsfahaniE. EmamgholipourS. BandarianF. Association between serum adropin levels and gestational diabetes mellitus; a case–control study.Gynecol. Endocrinol.2015311293994110.3109/09513590.2015.108168126376846
     [Google Scholar]
  35. ButlerA.A. TamC.S. StanhopeK.L. WolfeB.M. AliM.R. O’KeeffeM. St-OngeM.P. RavussinE. HavelP.J. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans.J. Clin. Endocrinol. Metab.201297103783379110.1210/jc.2012‑219422872690
     [Google Scholar]
  36. SoltaniS. Kolahdouz-MohammadiR. AydinS. YosaeeS. ClarkC.C.T. AbdollahiS. Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studies.Hormones (Athens)2022211152210.1007/s42000‑021‑00331‑034897581
     [Google Scholar]
  37. Guillemot-LegrisO. MutembereziV. CaniP.D. MuccioliG.G. Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma.Sci. Rep.2016611969410.1038/srep1969426795945
     [Google Scholar]
  38. JasaszwiliM. WojciechowiczT. BillertM. StrowskiM.Z. NowakK.W. SkrzypskiM. Effects of adropin on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes.Mol. Cell. Endocrinol.201949611053210.1016/j.mce.2019.11053231400396
     [Google Scholar]
  39. TopuzM. CelikA. AslantasT. DemirA.K. AydinS. AydinS. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus.J. Investig. Med.20136181161116410.2310/JIM.000000000000000324113736
     [Google Scholar]
  40. KocaogluC. BuyukinanM. ErdemS.S. OzelA. Are obesity and metabolic syndrome associated with plasma adropin levels in children?J. Pediatr. Endocrinol. Metab.20152811-121293129710.1515/jpem‑2015‑011726226125
     [Google Scholar]
  41. BousmpoulaA. KouskouniE. BenidisE. DemeridouS. Kapeta-KourkouliR. ChasiakouA. BakaS. Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles.Gynecol. Endocrinol.201834215315610.1080/09513590.2017.137949828937295
     [Google Scholar]
  42. SoltaniS. BeigrezaeiS. MalekahmadiM. ClarkC.C.T. AbdollahiS. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies.BMC Endocr. Disord.20232317310.1186/s12902‑023‑01327‑037029398
     [Google Scholar]
  43. MansourH.K. MakboulK. ElhalawanyS.H. IbrahimB.E. MarawanD.A. Marawan. D.A. A study of the assessment of serum adropin level as a risk factor of ischaemic heart disease in type 2 diabetes mellitus cases.Georgian Med. News2022328-329328-32911511710.1093/qjmed/hcad069.39736318853
     [Google Scholar]
  44. CelikE. YilmazE. CelikO. UlasM. TurkcuogluI. KaraerA. SimsekY. MinareciY. AydinS. Maternal and fetal adropin levels in gestational diabetes mellitus.jpme201341437538010.1515/jpm‑2012‑022723314506
     [Google Scholar]
  45. DąbrowskiF.A. JarmużekP. GondekA. Cudnoch-JędrzejewskaA. Bomba-OpońD. WielgośM. First and third trimester serum concentrations of adropin and copeptin in gestational diabetes mellitus and normal pregnancy.Ginekol. Pol.201687962963410.5603/GP.2016.005727723069
     [Google Scholar]
  46. AdamczakL. MantajU. GutajP. SkrypnikD. OzegowskiS. BogdanskiP. Wender-OzegowskaE. Adropin as a potential protective factor of metabolic complications in obese pregnant women with hyperglycaemia diagnosed in early pregnancy.J. Physiol. Pharmacol.202374110.26402/jpp.2023.1.0237245229
     [Google Scholar]
  47. VivekK. ReddyE.P. ThangappazhamB. RajH. Pérez-LópezF.R. VarikasuvuS.R. Maternal adropin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis.Gynecol. Endocrinol.202238210510910.1080/09513590.2021.196370334378485
     [Google Scholar]
  48. ChenX. ChenS. ShenT. YangW. ChenQ. ZhangP. YouY. SunX. XuH. TangY. MiJ. YangY. LingW. Adropin regulates hepatic glucose production via PP2A/AMPK pathway in insulin-resistant hepatocytes.FASEB J.2020348100561007210.1096/fj.202000115RR32579277
     [Google Scholar]
  49. ThapaD. XieB. ManningJ.R. ZhangM. StonerM.W. HuckesteinB.R. EdmundsL.R. ZhangX. DedousisN.L. O’DohertyR.M. JurczakM.J. ScottI. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production.Physiol. Rep.201978e1404310.14814/phy2.1404331004398
     [Google Scholar]
  50. GaoS. McMillanR.P. ZhuQ. LopaschukG.D. HulverM.W. ButlerA.A. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance.Mol. Metab.20154431032410.1016/j.molmet.2015.01.00525830094
     [Google Scholar]
  51. YingT. WuL. LanT. WeiZ. HuD. KeY. JiangQ. FangJ. Adropin inhibits the progression of atherosclerosis in ApoE-/-/Enho-/- mice by regulating endothelial-to-mesenchymal transition.Cell Death Discov.20239140210.1038/s41420‑023‑01697‑337903785
     [Google Scholar]
  52. WuL. FangJ. ChenL. ZhaoZ. LuoY. LinC. FanL. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients.Clin. Chem. Lab. Med.20145251810.1515/cclm‑2013‑084424323892
     [Google Scholar]
  53. ZhaoL.P. YouT. ChanS.P. ChenJ.C. XuW.T. Adropin is associated with hyperhomocysteine and coronary atherosclerosis.Exp. Ther. Med.20161131065107010.3892/etm.2015.295426998038
     [Google Scholar]
  54. ZhengJ. LiuM. ChenL. YinF. ZhuX. GouJ. ZengW. LvZ. Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis.Cardiovasc. Diagn. Ther.2019911710.21037/cdt.2018.07.0930881871
     [Google Scholar]
  55. UysalB.A. KuyumcuM.S. Serum irisin and adropin levels may be predictors for coronary artery ectasia.Clin. Exp. Hypertens.202244322322710.1080/10641963.2021.201860134994255
     [Google Scholar]
  56. AydinS. KulogluT. AydinS. KalayciM. YilmazM. ÇakmakT. ErenM.N. Elevated adropin: A candidate diagnostic marker for myocardial infarction in conjunction with troponin-I.Peptides201458919710.1016/j.peptides.2014.06.00124932661
     [Google Scholar]
  57. AltamimiT.R. GaoS. KarwiQ.G. FukushimaA. RawatS. WaggC.S. ZhangL. LopaschukG.D. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency.Metabolism201998374810.1016/j.metabol.2019.06.00531202835
     [Google Scholar]
  58. AdıyamanM.Ş. Canpolat ErkanR.E. Kayaİ. Aba AdıyamanÖ. Serum adropin level in the early period of ST-elevation myocardial infarction and its relationship with cobalamin and folic acid.Cureus20221412e3274810.7759/cureus.3274836686140
     [Google Scholar]
  59. MeierP. GloeklerS. ZbindenR. BeckhS. de MarchiS.F. ZbindenS. WustmannK. BillingerM. VogelR. CookS. WenaweserP. TogniM. WindeckerS. MeierB. SeilerC. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements.Circulation2007116997598310.1161/CIRCULATIONAHA.107.70395917679611
     [Google Scholar]
  60. VuralA. KurtD. KaragözA. EmecenÖ. AydinE. The relationship between coronary collateral circulation and serum adropin levels.Cureus2023152e3516610.7759/cureus.3516636949994
     [Google Scholar]
  61. ChangX. JinF. WangL. JiangY. WangP. LiuJ. ZhaoL. Adropin – A new player in energy regulation predicts long-term prognosis of patients with acute myocardial infarction.Heliyon202397e1780310.1016/j.heliyon.2023.e1780337455994
     [Google Scholar]
  62. GulenB. EkenC. KucukdagliO.T. SerinkenM. KocyigitA. KılıcE. UyarelH. Adropin levels and target organ damage secondary to high blood pressure in the ED.Am. J. Emerg. Med.201634112061206410.1016/j.ajem.2016.04.01427592461
     [Google Scholar]
  63. SalmanpourM. SooriR. H’midaC. HalouaniJ. ClarckC.T. PournematiP. YariS.M. TrabelsiK. AmmarA. ChtourouH. TaheriM. The effect of 8 weeks of combined interval (resistance-interval training) and combined endurance (endurance-resistance training) on plasma levels of adropin and nitric oxide in males with high blood pressure.Ir. J. Med. Sci.202219162559256810.1007/s11845‑021‑02873‑z35029793
     [Google Scholar]
  64. AfşinA. BozyılanE. AsoğluR. YavuzF. DündarA. Effects of eight weeks exercise training on serum levels of adropin in male volleyball players.Horm. Mol. Biol. Clin. Investig.202142329730210.1515/hmbci‑2020‑009433794077
     [Google Scholar]
  65. NergizS. AltinkayaS.O. Kurt Ömürlüİ. YukselH. KüçükM. Demircan SezerS. Circulating adropin levels in patients with endometrium cancer.Gynecol. Endocrinol.201531973073510.3109/09513590.2015.106548026172926
     [Google Scholar]
  66. StelcerE. MileckaP. KomarowskaH. JopekK. TyczewskaM. SzyszkaM. LesniczakM. SuchorskaW. BekovaK. SzczepaniakB. RuchalaM. KarczewskiM. WierzbickiT. SzaflarskiW. MalendowiczL.K. RucinskiM. Adropin stimulates proliferation and inhibits adrenocortical steroidogenesis in the human adrenal carcinoma (HAC15) cell line.Front. Endocrinol. (Lausanne)20201156137010.3389/fendo.2020.56137033133015
     [Google Scholar]
  67. HuJ. WuQ. DingQ. WuW. LiQ. ZhengZ. High level of adropin promotes the progression of pancreatic ductal adenocarcinoma.Curr. Cancer Drug Targets2023Online ahead of print10.2174/011568009626720323102409360137990897
     [Google Scholar]
  68. JiaL. LiaoL. JiangY. HuX. LuG. XiaoW. GongW. JiaX. Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression.BMC Cancer2023231104210.1186/s12885‑023‑11519‑537904094
     [Google Scholar]
  69. YolbasS. KaraM. YilmazM. AydinS. KocaS.S. Serum adropin level and ENHO gene expression in systemic sclerosis.Clin. Rheumatol.20163561535154010.1007/s10067‑016‑3266‑127079850
     [Google Scholar]
  70. GunrajR.E. YangC. LiuL. LarochelleJ. Candelario-JalilE. Protective roles of adropin in neurological disease.Am. J. Physiol. Cell Physiol.20233243C674C67810.1152/ajpcell.00318.202236717106
     [Google Scholar]
  71. YangC. DeMarsK.M. HawkinsK.E. Candelario-JalilE. Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions.Peptides201681293710.1016/j.peptides.2016.03.00927020249
     [Google Scholar]
  72. CinkirU. BirL.S. TopsakalS. Avci CicekE. TekinS. Investigation of blood leptin and adropin levels in patients with multiple sclerosis.Medicine (Baltimore)202110037e2724710.1097/MD.000000000002724734664869
     [Google Scholar]
  73. Demi̇rdöğenF. AkdağT. GündüzZ.B. OdabaşF.Ö. Investigation of serum adropin levels and its relationship with hypothalamic atrophy in patients with multiple sclerosis.Mult. Scler. Relat. Disord.20226610394810.1016/j.msard.2022.10394835843143
     [Google Scholar]
  74. AlgulS. OzcelikO. Evaluating the energy regulatory hormones of nesfatin-1, irisin, adropin and preptin in multiple sclerosis.Mult. Scler. Relat. Disord.20226810422110.1016/j.msard.2022.10422136228401
     [Google Scholar]
  75. AggarwalG. MorleyJ.E. VellasB. NguyenA.D. ButlerA.A. GuyonnetS. CarriéI. BrigitteL. FaisantC. LalaF. DelrieuJ. VillarsH. CombrouzeE. BadufleC. ZuerasA. AndrieuS. CantetC. MorinC. Van KanG.A. DupuyC. RollandY. CaillaudC. OussetP-J. LalaF. WillisS. BellevilleS. GilbertB. FontaineF. DartiguesJ-F. MarcetI. DelvaF. FoubertA. CerdaS. Marie-Noëlle-Cuffi CostesC. RouaudO. ManckoundiaP. QuipourtV. MarilierS. FranonE. BoriesL. PaderM-L. BassetM-F. LapoujadeB. FaureV. TongM.L.Y. Malick-LoiseauC. Cazaban-CampistronE. DesclauxF. BlatgeC. DantoineT. Laubarie-MouretC. SaulnierI. ClémentJ-P. PicatM-A. Bernard-BourzeixL. WilleboisS. DésormaisI. CardinaudN. BonnefoyM. LivetP. RebaudetP. GédéonC. BurdetC. TerracolF. PesceA. RothS. ChaillouS. LouchartS. SudresK. LebrunN. Barro-BelayguesN. TouchonJ. BennysK. GabelleA. RomanoA. TouatiL. MarelliC. PaysC. RobertP. Le DuffF. GervaisC. GonfrierS. GasnierY. BordesS. BegorreD. CarpuatC. KhalesK. LefebvreJ-F. El IdrissiS.M. SkolilP. SallesJ-P. DufouilC. LehéricyS. ChupinM. ManginJ-F. BouhayiaA. AllardM. RicolfiF. DuboisD. MartelM.P.B. CottonF. BonaféA. ChanaletS. HugonF. BonnevilleF. CognardC. CholletF. PayouxP. VoisinT. DelrieuJ. PeifferS. HitzelA. AllardM. ZancaM. MonteilJ. DarcourtJ. MolinierL. DerumeauxH. CostaN. PerretB. VinelC. Caspar-BauguilS. Olivier-AbbalP. AndrieuS. CantetC. ColeyN. Low circulating adropin concentrations predict increased risk of cognitive decline in community-dwelling older adults.Geroscience2023461897911Online ahead of print10.1007/s11357‑023‑00824‑337233882
     [Google Scholar]
  76. BanerjeeS. GhoshalS. GirardetC. DeMarsK.M. YangC. NiehoffM.L. NguyenA.D. JayanthP. HoelscherB.A. XuF. BanksW.A. HansenK.M. ZhangJ. Candelario-JalilE. FarrS.A. ButlerA.A. Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging mice.NPJ Aging Mech. Dis.2021712310.1038/s41514‑021‑00076‑534462439
     [Google Scholar]
  77. GhoshalS. BanerjeeS. ZhangJ. NiehoffM.L. FarrS.A. ButlerA.A. Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL/6J mice.Peptides202114617067810.1016/j.peptides.2021.17067834695512
     [Google Scholar]
  78. YangC. LiuL. LavayenB.P. LarochelleJ. GunrajR.E. ButlerA.A. Candelario-JalilE. Therapeutic benefits of adropin in aged mice after transient ischemic stroke via reduction of blood-brain barrier damage.Stroke202354123424410.1161/STROKEAHA.122.03962836305313
     [Google Scholar]
  79. SaçmacıH. ÇakırM. ÖzcanS.S. Adropin and MOTS‐c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?J. Biochem. Mol. Toxicol.2023372e2324610.1002/jbt.2324636303331
     [Google Scholar]
  80. SayınO. TokgözY. ArslanN. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease.J. Pediatr. Endocrinol. Metab.2014275-647948410.1515/jpem‑2013‑029624468600
     [Google Scholar]
  81. KutluO. AltunÖ. DikkerO. AktaşŞ. ÖzsoyN. ArmanY. Özgün ÇilE. ÖzcanM. Aydın YoldemirŞ. AkarsuM. Toprakİ.D. KırnaK. KutluY. ToprakZ. EruzunH. TükekT. Serum Adropin levels are reduced in adult patients with nonalcoholic fatty liver disease.Med. Princ. Pract.201928546346910.1159/00050010630995640
     [Google Scholar]
  82. LiN. XieG. ZhouB. QuA. MengH. LiuJ. WangG. Serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease.Front. Physiol.20211269616310.3389/fphys.2021.69616334366886
     [Google Scholar]
  83. InalZ.O. ErdemS. GederetY. DuranC. KucukaydinZ. KurkuH. SakaryaD.K. The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS.Endokrynol. Pol.201569213514110.5603/EP.a2018.000229465156
     [Google Scholar]
  84. KeY. HuJ. ZhuY. WangY. ChenS. LiuS. Correlation between circulating adropin levels and patients with PCOS: an updated systematic review and meta-analysis.Reprod. Sci.202229123295331010.1007/s43032‑022‑00841‑135015289
     [Google Scholar]
  85. VarikasuvuS.R. ReddyE.P. ThangappazhamB. VarshneyS. DasV.L. MunikumarM. Adropin levels and its associations as a fat-burning hormone in patients with polycystic ovary syndrome: a correlational meta-analysis.Gynecol. Endocrinol.2021371087988410.1080/09513590.2021.195013634241553
     [Google Scholar]
  86. YeZ. ZhangC. ZhaoY. Potential effects of adropin on systemic metabolic and hormonal abnormalities in polycystic ovary syndrome.Reprod. Biomed. Online20214251007101410.1016/j.rbmo.2021.01.02033612434
     [Google Scholar]
  87. MajeedA.A. Al-QaisiA.H.J. AhmedW.A. The comparison of irisin, subfatin, and adropin in normal-weight and obese polycystic ovary syndrome patients.Iran. J. Med. Sci.202449635035810.30476/ijms.2023.99130.311738952638
     [Google Scholar]
  88. RizkF.H. El SaadanyA.A. ElshamyA.M. Abd EllatifR.A. El-GuindyD.M. HelalD.S. HamamaM.G. El-SharnobyJ.A.E.H. Abdel GhafarM.T. FaheemH. Ameliorating effects of adropin on letrozole-induced polycystic ovary syndrome via regulating steroidogenesis and the microbiota inflammatory axis in rats.J. Physiol.20246021536213639Epub ahead of print10.1113/JP28579338980987
     [Google Scholar]
  89. KarumanchiS.A. Angiogenic factors in preeclampsia: From diagnosis to therapy.Hypertension20166761072107910.1161/HYPERTENSIONAHA.116.0642127067718
     [Google Scholar]
/content/journals/cp/10.2174/0115701646301720240830070246
Loading
Advances in Research on Adropin: Potential Implications for Clinical Diagnosis and Possible Treatment – A Mini-Review
Curr. Proteomics 21, 205 (2024); https://doi.org/10.2174/0115701646301720240830070246
/content/journals/cp/10.2174/0115701646301720240830070246
/content/journals/cp/10.2174/0115701646301720240830070246
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Adropin; cardiovascular diseases; diabetes mellitus; energy homeostasis; liver; obesity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test